Characteristics of older patients undergoing postremission therapy for AML (N = 40)
| Characteristics . | Median (25th, 75th percentiles) or % . |
|---|---|
| Demographics | |
| Age, y | 68.7 (66.0, 75.5) |
| 60-69 | 57.5 |
| 70-79 | 32.5 |
| ≥80 | 10.0 |
| Sex (male) | 57.5 |
| Race (white) | 95.0 |
| Education level* | |
| Less than high school | 18.0 |
| High school | 25.6 |
| College/above | 56.4 |
| Clinical | |
| Hemoglobin, g/dL | 10.9 (10.3, 12.2) |
| Lactate dehydrogenase, U/L | 186.5 (171.0, 215.5) |
| White blood cell count, ×103/μL | 6.7 (4.8, 9.0) |
| Creatinine, mg/dL | 0.9 (0.8, 1.1) |
| Body mass index, kg/m2 | 25.4 (22.8, 28.8) |
| ECOG score (≤1)† | 68.4 |
| Prior myelodysplastic syndrome | 15.0 |
| Cytogenetic risk group* | |
| Favorable | 5.1 |
| Intermediate | 71.8 |
| Poor | 23.1 |
| Coronary artery disease | 15.0 |
| Chronic obstructive pulmonary disease | 12.5 |
| Diabetes mellitus | 22.5 |
| Congestive heart failure | 7.5 |
| Antidepressant use at diagnosis | 17.5 |
| Induction treatment | |
| Anthracycline+cytarabine | 52.5 |
| Anthracycline+cytarabine+etoposide | 20.0 |
| Other | 27.5 |
| Received 1 cycle of induction therapy vs >1 | 60 |
| Postremission therapy | |
| Initial therapy | |
| Cytarabine | 77.5 |
| Hypomethylating agent | 10 |
| Other (cytarabine+bortezomib, n = 1; cyclophosphamide+etoposide, n = 3; cytarabine+mitoxantrone, n = 1) | 12.5 |
| Dose of cytarabine consolidation, g/m2 | |
| 0.5 | 7.5 |
| 1.0 | 17.5 |
| 1.5 | 37.5 |
| 2.0 | 27.5 |
| Received peripheral blood stem cell transplantation | 22.5 |
| Geriatric assessment scores | |
| Cognition | |
| Modified Mini-Mental State Exam‡ (range 0-100, impairment <77) | 88.0 (81.0, 92.0); 20.0% impaired |
| Psychological function | |
| Center for Epidemiologic Studies Depression Scale (range 0-60, impairment ≥16)* | 8.0 (3.0, 18.0); 25.6% impaired |
| Distress Thermometer (range 0-10, impairment ≥4)* | 3.0 (0.0, 5.0); 35.9% impaired |
| Comorbidity | |
| HCT-CI (impairment >2) | 2.0 (1.0, 4.0); 40.0% impaired |
| No. of prescription medications | 8.0 (5.0-10.5); 70.0% impaired |
| Physical function§ | |
| ADL subscale | 1.3 (1.0, 1.6); 65.0% impaired |
| Instrumental ADL subscale¶ | 1.8 (1.2, 2.8); 60.0% impaired |
| Mobility subscale|| | 2.7 (1.8, 4.3); 82.5% impaired |
| SPPB (range 0-12, impairment <9) | 6.0 (0.0, 9.0); 70.0% impaired |
| Grip strength, kg | |
| Male (impairment <26) | 36.0 (22.0, 45.0); 21.7% impaired |
| Female (impairment <16) | 20.0 (18.0, 26.0); 0% impaired |
| Characteristics . | Median (25th, 75th percentiles) or % . |
|---|---|
| Demographics | |
| Age, y | 68.7 (66.0, 75.5) |
| 60-69 | 57.5 |
| 70-79 | 32.5 |
| ≥80 | 10.0 |
| Sex (male) | 57.5 |
| Race (white) | 95.0 |
| Education level* | |
| Less than high school | 18.0 |
| High school | 25.6 |
| College/above | 56.4 |
| Clinical | |
| Hemoglobin, g/dL | 10.9 (10.3, 12.2) |
| Lactate dehydrogenase, U/L | 186.5 (171.0, 215.5) |
| White blood cell count, ×103/μL | 6.7 (4.8, 9.0) |
| Creatinine, mg/dL | 0.9 (0.8, 1.1) |
| Body mass index, kg/m2 | 25.4 (22.8, 28.8) |
| ECOG score (≤1)† | 68.4 |
| Prior myelodysplastic syndrome | 15.0 |
| Cytogenetic risk group* | |
| Favorable | 5.1 |
| Intermediate | 71.8 |
| Poor | 23.1 |
| Coronary artery disease | 15.0 |
| Chronic obstructive pulmonary disease | 12.5 |
| Diabetes mellitus | 22.5 |
| Congestive heart failure | 7.5 |
| Antidepressant use at diagnosis | 17.5 |
| Induction treatment | |
| Anthracycline+cytarabine | 52.5 |
| Anthracycline+cytarabine+etoposide | 20.0 |
| Other | 27.5 |
| Received 1 cycle of induction therapy vs >1 | 60 |
| Postremission therapy | |
| Initial therapy | |
| Cytarabine | 77.5 |
| Hypomethylating agent | 10 |
| Other (cytarabine+bortezomib, n = 1; cyclophosphamide+etoposide, n = 3; cytarabine+mitoxantrone, n = 1) | 12.5 |
| Dose of cytarabine consolidation, g/m2 | |
| 0.5 | 7.5 |
| 1.0 | 17.5 |
| 1.5 | 37.5 |
| 2.0 | 27.5 |
| Received peripheral blood stem cell transplantation | 22.5 |
| Geriatric assessment scores | |
| Cognition | |
| Modified Mini-Mental State Exam‡ (range 0-100, impairment <77) | 88.0 (81.0, 92.0); 20.0% impaired |
| Psychological function | |
| Center for Epidemiologic Studies Depression Scale (range 0-60, impairment ≥16)* | 8.0 (3.0, 18.0); 25.6% impaired |
| Distress Thermometer (range 0-10, impairment ≥4)* | 3.0 (0.0, 5.0); 35.9% impaired |
| Comorbidity | |
| HCT-CI (impairment >2) | 2.0 (1.0, 4.0); 40.0% impaired |
| No. of prescription medications | 8.0 (5.0-10.5); 70.0% impaired |
| Physical function§ | |
| ADL subscale | 1.3 (1.0, 1.6); 65.0% impaired |
| Instrumental ADL subscale¶ | 1.8 (1.2, 2.8); 60.0% impaired |
| Mobility subscale|| | 2.7 (1.8, 4.3); 82.5% impaired |
| SPPB (range 0-12, impairment <9) | 6.0 (0.0, 9.0); 70.0% impaired |
| Grip strength, kg | |
| Male (impairment <26) | 36.0 (22.0, 45.0); 21.7% impaired |
| Female (impairment <16) | 20.0 (18.0, 26.0); 0% impaired |
For Modified Mini-Mental State Exam, SPPB, and grip strength, a higher score reflects better function. For Center for Epidemiologic Studies Depression, Distress Thermometer, ADL, Instrumental ADL, Mobility, and HCT-CI, a higher score reflects worse function.
One subject had missing data.
Two subjects had missing data.
Three subjects had missing data.
Results based on subjects with calculable survey scores.
Twelve subjects had missing data.
Ten subjects had missing data.